FROM:
Am J Clin Nutr. 1997 (Apr); 65 (4): 1011–1017 ~ FULL TEXT
K Shane Broughton, Cody S Johnson, Bobin K Pace,
Michael Liebman, and Kent M Kleppinger
Nutrition/Department of Family and Consumer Science,
University of Wyoming,
Laramie 82071, USA
Why was this study done?
Asthma is one of the more common childhood conditions and effects around eight percent of adults. The prevalence has been increasing since the 1980s. This study was designed to help understand the connection between omega 3 supplementation, inflammatory markers, and asthma symptoms.
What This Study Found
Supplementing with omega-3 fish oils, in a two to one (omega 3/omega6) ratio reduced inflammatory markers (leukotrienes) and symptoms in most, but not all, asthmatic participants in the study.
|
Asthma may respond to dietary modification,
thereby reducing the need for pharmacologic agents. This study
determined the effectiveness of n-3 polyunsaturated fatty acid
(PUFA) ingestion in ameliorating methacholine-induced respiratory distress in an asthmatic population. The ability of urinary leukotriene excretion to predict efficacy of n-3 PUFA ingestion was assessed. After n-3 PUFAs in ratios to n-6 PUFAs of 0.1:1 and 0.5: 1 were ingested sequentially for 1 mo each; patient respiratory indexes were assessed after each treatment. Forced vital capacity (FVC), forced expiratory volume for 1 s (FEV1), peak expiratory flow (PEF), and forced expiratory flow 25-75% (FEF25-75) were measured along with weekly 24-h urinary leukotriene concentrations. With low n-3 PUFA ingestion, methacholine-induced respiratory distress increased. With high n-3 PUFA ingestion, alterations in urinary 5-series leukotriene excretion predicted treatment efficacy. Elevated n-3 PUFA ingestion resulted in a positive methacholine bronchoprovocation dose change in > 40% of the test subjects (responders). The provocative dose to cause a 20% reduction (PD,0) in FEy1, P/C, PEF, and FEF25-75 values could not be calculated because of a lack of significant respiratory reduction. Conversely, elevated n-3 PUFA ingestion caused some of the patients (nonresponders) to further lose respiratory capacity. Five-series leukotnene excretion with high n-3 PUFA ingestion was significantly greater for responders than for nonresponders. A urinary ratio of 4-series to 5-series leukotrienes < 1, induced by n - 3 PUFA ingestion, may predict respiratory benefit.
KEY WORDS Asthma, n-3 fatty acids, leukotriene,
FEy1, forced expiratory volume for 1 s, methacholine, n-6
fatty acids, 4-series leukotrienes, 5-series leukotrienes, fish oil
From the FULL TEXT Article:
INTRODUCTION
Asthma may affect 5% of the Western population [1] and
is the most common chronic condition of childhood, with
between 20% and 25% of all children experiencing wheezing at
some point in their lives. Airflow obstruction associated with
bronchial asthma is composed of four components: airway wall
swelling, elevated lurninal secretion, increased presence of
inflammatory cells in the airway wall, and muscle contraction. [2] Numerous chemical mediators released during degranulation,
including leukotrienes, can elicit an allergic reaction.
Four-series sulfidopeptide leukotrienes (SPLTs: LTC4,
LTD4, and LTE4) increase postcapillary permeability, are potent
stimulators of airway smooth muscle cells, mediate pulmonary
asthma through their involvement in vasoconstriction
and mucus secretion [3], and are ≤ 1000 times more potent
than histamine on a molar basis. LTC4 and LTD4 can stimulate
contraction of smaller airways of pulmonary parenchymal tissue [4] and smooth muscle of lobar and segmental bronchi in
vitro. [3] Leukotrienes have been detected in blood, bronchoalveolar lavage fluid, and urine of asthmatics and are produced by cells that mediate pulmonary inflammation in asthma. [5]
The principal 5-lipoxygenase product of human eosinophils [6] and mast cells [7] is LTC4, the initial SPLT synthesized.
LTC4 appears to be involved in asthma through amplification
of local processes and the induction of cooperating cells in the
airways [8] to produce LTB4 and 5S-hydroxy-6,8,l 1,14
(E,Z,Z,Z)-eicosatetraenoic acid. Although LTC4 and LTD4 are
the most biologically potent SPLTs, LTE4 and N-acetyl-LTE4
are the primary urinary rnetabolites; there is no evidence of
urinary LTC4 and LTD4 excretion. [9]
The asthmatic response can be precipitated by numerous
initiators, including aspirin ingestion and exercise. Urinary
leukotriene concentrations are elevated after induction of
asthma by exercise [10], antigen [11], or aspirin. [12] It is unknown what role, if any, the 5-series SPLTs (LTC5, LTD5.
and LTE5) play in this response. These leukotrienes originate
from eicosapentaenoic acid (EPA, 20:5n-3), found in fish and
fish oil.
The effect of leukotrienes in various disease processes [13],
particularly asthma [6], has been reviewed extensively. Current
clinical and biomedical research on asthma has focused on the
development of pharmacologic agents that do the following:
I) inhibit the release of arachidonic acid (20:4n-6) to inhibit
leukotriene formation [14];
2) inhibit 5-lipoxygenase, which is necessary for the synthesis of leukotriene precursors [15]; or
3) serve as leukotriene receptor antagonists. [16]
Leukotriene
receptor antagonists are designed to inhibit the action of LTC4
and LTD4 because these are the two most potent leukotrienes.
High dietary intake oflinoleic acid (18:2n-6) may indirectly
elevate leukotriene synthesis and contribute to leukotrieneinduced exacerbation of the asthmatic response. Current 18: 2n-6 intakes in much of the US population may be as high as 10% of total energy because of perceived health benefits associated with substitution of n-6 polyunsaturated fatty acids
(PUFAs) for saturated fats in the diet. In the body, 18:2n-6
can be converted to 20:4n-6 and thus serve as a leukotriene
precursor. It has been shown that n-3 PUFA ingestion results
in a reduction of 4-series and total leukotriene biosynthesis,
apparently induced through reductions in tissue 20:4n-6 concentrations. [17]
This study focused on the potential effect of n-3 PUFAs in
ameliorating asthmatic bronchial hyperresponsiveness induced
by a methacholine challenge, possibly mediated via n-3 PUFA-induced alterations in leukotriene formation. Bronchial
responsiveness to methacholine has been proven to be a valid
means of assessing the tendency of airways to constrict with
specific stimuli. [18] Previous studies assessed n-3 PUFA
effects on asthma [19–23] but did not examine relations with
urinary metabolites that may predict efficacy in ameliorating
bronchial hyperresponsiveness to a stimulus. Specifically, this
study was designed to determine whether and to what extent
the asthmatic response can be reduced by differing intakes of
n-3 PUFAs.
SUBJECTS AND METHODS
Subjects
Twenty-six, nonsmoking atopic asthmatic subjects (mean
age: 22 y; range: 19-25 y) were recruited from the Laramie,
WY, community. Subjects showed nonspecific bronchial responsiveness
to methacholine with a forced expiratory volume
in I s (FEy1) > 70% of predicted. Subjects were screened for
overall health status, use of drugs that affect asthma or eicosanoid
synthesis, and fish (or fish oil) consumption. Potential
subjects who ingested fish oil supplements in any amount or
who consumed more than one fish meal per week were not
selected. Individuals with bleeding disorders or a history of
delayed clotting time were not considered. Subjects were taking
various treatments, including inhalants such as salbutamol,
steroids, and oral ingestion of theophyllines. No subject had
had an upper respiratory tract infection or exacerbation of
asthma in the 6 wk before study initiation. Nonsteroidal antiinflammatory
drugs were not allowed during the study. The
study was approved by the Human Subjects Review Board at
the University of Wyoming and informed consent was obtained
from all participants after the study design and expectations
were described to them. Nineteen subjects completed the study.
Seven-day food records for all participants were examined to
determine normal n-6 PUFA consumption. Three random 3-d
diet analyses were conducted throughout the study to monitor
changes in diet patterns and n-6 PUFA intakes. Subjects
participated in a 2-mo study examining the effect of variations
in ratios of n-3 to n-6 PUFAs on respiratory measures and
urinary metabolites. Treatment order for all participants was as
follows: low fish-oil supplementation with a ratio of n-3 to
n-6 PUFAs of 0.l:l followed by high fish-oil supplementation
with a ratio of n-3 to n-6 PUFAs of 0.5: 1. A washout period
between fish-oil treatments was not deemed necessary because
low n-3 PUFA intake was followed by high n-3 PUFA intake
in all subjects. It was shown previously that tissues retain n-3
PUFAs even when no n - 3 PUFA is consumed for an extended
period. [17] Thus, in this case, a washout period would have
had to be inconveniently long and may not have resulted in a
marked decrease in tissue n-3 PUFA content.
Each treatment period lasted 4 wk. Fish-oil regimens at both
n- 3 PUFA intakes were individualized for each participant.
Individualization of n-3 PUFA ingestion was based on the
dietary analysis of each subject’s n-6 PUFA intake. Encapsulated
n-3 PUFA was provided in the appropriate amounts, ie,
in ratios with n-6 PUFAs of 0.1 : 1 and 0.5: 1. Encapsulated fish oil was donated by the Shaklee Corporation (Hayward, CA).
Subjects were given the appropriate number of oil capsules
divided into daily allotments at the beginning of each study
week. Subjects were questioned weekly regarding compliance
with fish-oil treatments throughout the entire study. The average increase in energy was < 1 .5% and thus of minimal significance.
Two 24-h urine samples were collected in urine collection
bottles and transferred to refrigerated opaque bottles containing
methanol and formic acid on the 2 d immediately preceding the
study, to serve as baseline samples. After determination of
volume, samples were further acidified with formic acid to a
final concentration of 3 mmollL and diluted with methanol to
a final concentration of 10%. FEy1, peak expiratory flow
(PEF), and forced expiratory flow 25-75% (FEF25-75), as assessments of large, medium, and small airway capacity, respectively, and forced vital capacity (FVC) were obtained immediately preceding the study to serve as baseline values. Twentyfour-hour urine samples were obtained the last day of each
week during each 4-wk oil supplementation period to monitor
potential progressive changes in eicosanoid metabolism. After
determination of baseline and treatment urine volumes, leukotrienes were extracted from a 200-mL aliquot and frozen at
-80 #{176}Cfor subsequent analysis.
Study protocol
At baseline and after each 4-wk treatment period, patients
entered the participating physician’s office for assessment of
respiratory status via FVC, FEV1, PEF, and FEF25-75 after a methacholine (Provocholine, Roche Laboratories, Nutley, NJ) challenge. Methacholine was administered sequentially
through five inhalations in serial concentrations with a Salter
Lab nebulizer (Series 8900; Salter Labs, Arvin, CA) at a flow
rate of 7-8 L/min, such that the total administered was 0, 0.125,
1.375, 13.88, and 63.88 cumulative units. All respiratory indexes were determined within 5 mm. The procedure was terrninated if there was a 20% reduction in FEV1 compared with a baseline saline (0.9% NaCl with 0.4% phenol, pH 7.0) solution or when 63.88 cumulative units had been administered. If there was a reduction of 15-19% in FEy1, the challenge was repeated at that concentration or the next higher concentration as long as the cumulative units did not exceed 63.88. Methacholine challenge values for FVC, FEV1, PEF, and FEF25-75 were obtained by the attending physician using a Brentwood 2000 spirometer (Brentwood, CA).
Leukotriene analysis
Leukotrienes were extracted from 200 mL freshly collected,
acidified urine. Urine was selected for analysis because it has
been shown to provide a fairly accurate estimate of leukotriene
biosynthesis. [9, 11] One hundred nanograms prostaglandin B1 was added to the 200-mL aliquot as an internal standard.
Leukotrienes were isolated by solid-phase extraction over C-18
cartridges (Supelclean LC-18; Supelco, Inc. Bellefonte, PA) [24] that were prewashed sequentially with 10 rnL methanol, S
mL water, and 5 mL hexane. After application of urine, cartridges were washed sequentially with 10 mL methanol:water
(1:9, by vol), 10 mL water, and 5 ml hexane, followed by
elution of leukotrienes with 2 mL methanol. After elution,
leukotriene extractions were stored in methanol at -80°C for subsequent analysis.
For analysis [25], samples were evaporated to dryness under
nitrogen; the resulting residue was reconstituted in an HPLC
solvent system of methanol:water (65:35, by vol), pH 4.68,
containing 5 mmol ammonium acetate/L and I mmol EDTAIL.
All samples were analyzed in duplicate with averages being
used for statistical analysis. The leukotrienes were separated by
reversed-phase HPLC on a Partisphere C-18 column (6 mm X 12.5 cm; Whatman, Hillsboro, OR) with a flow rate of 1.0 mL/min and quantified by using a Hewlett-Packard spectrophotometer
( 10409A Diode Array; Hewlett-Packard, Liverpool,
NY) by monitoring at 280 nrn. All leukotrienes were
identified by their distinctive ultraviolet absorption spectra and
comparison of retention times with known standards. Leukotrienes
were quantified against the internal PGB, standard by
using extinction coefficients of authentic standards (26). Fourseries
leukotrienes, ie, LTE4, N-acetyl-LTE4, and their 1 1-
trans-isomers were pooled for analysis. Five-series leukotrienes
in the form of LTE5 and its 1 I-trans-isomer were
combined for analysis. LTE4, LTE5, and N-acetyl LTE4 were
purchased from Caymen Chemical (Ann Arbor, MI).
Statistics
The minimal number of samples for each assay was determined
by statistical analyses of the power to detect a physiologically
significant difference between treatments. Estimates
of variance used in the design were computed from previous
experiments. As an example, urinary leukotriene concentrations
were judged to be clinically different if a diet-induced
decrease of 15% occurred. For 90% confidence of detecting a
15% change in urine leukotriene concentrations, the number of
replicates required is seven, based on our experimental history.
Differences between baseline, low n-3 PUFA, and high n-3
PUFA ingestion with respect to the effect on the respiratory
factors FVC, FEV1, PEF, and FEF25-75 at each methacholine
dose and the provocative dose to cause a 20% reduction in each
of these indexes (PD20) were assessed by one-way analysis of
variance (ANOVA). Differences between baseline, low n-3
PUFA. and high n-3 PUFA ingestion with respect to effect on
urinary total and leukotriene subfractions were assessed by
two-way ANOVA (ie, responder or nonresponder and n-3
PUFA treatment) using a split-plot factorial design. [27] All
statistical analyses were conducted with SAS software (Statistical Analysis Systems Institute, Inc, Cary, NC). When overall differences were detected, specific treatment differences were assessed by using Duncan‘s protected least-significant-difference test. Significance was determined at P < 0.05. Values are expressed as means ± SEMs with a common n = 19 in
participant cases, n = 9 in responder cases, and n = 10 in
nonresponder cases, unless stated otherwise.
RESULTS
All participants tolerated the study well and body weights
were relatively constant for the duration of the study. No side
effects other than fishy hiccups and occasional mild gastrointestinal
discomfort were reported on questioning. Problems
with hiccups and gastrointestinal discomfort were alleviated by
changing n-3 PUFA ingestion times from morning to evening
before sleep.
Pulmonary function tests during methacholine bronchonrovocation
Ingestion of n-3 PUFAs at a dietary ratio of n-3 to n-6
PUFAs of 0. 1: 1 resulted in a pattern suggesting greater breathing
difficulty compared with baseline at any methacholine
dose. Respiratory measures generally decreased two- to threefold
faster (% change) with ingestion of n-3 PUFAs in this
ratio to n-6 PUFAs (Figure 1). PD20 values for FVC, FEV1,
PEF, and FEF25-75 were reduced by 51%, 89%, 65%, and 92%,
respectively (Table 1).
When n-3 PUFA ingestion was increased to a ratio with
n-6 PUFAs of 0.5:1, respiratory measures in the total
sample population were not significantly different from
baseline responses. On examination of these data, it became
evident that breathing capacity was actually improved in 9
ofthe 19 participants with high n-3 PUFA ingestion. Those
characterized by no reduction in respiratory measures with
increased methacholine challenge after the period of elevated
n-3 PUFA intake were referred to as responders.
When data from the responders were summarized separately,
there was virtually no decrease in any respiratory
index with increasing methacholine challenge, with the exception
of a minimal change in PEF and FEF25-75 values at
a cumulative dose of 63.88 units. PD20 values with elevated
n-3 PUFA ingestion in this subpopulation could not be
calculated because of improvements in respiratory indexes
(ie, respiratory responses were never reduced by 20%, regardless
of methacholine dose) (Table 1). Note that at study
initiation, respiratory indexes of responders were not significantly different from those of the other 10 participants.
Those showing respiratory reductions with increased methacholine
challenge, even with elevated n-3 PUFA intake
were referred to as nonresponders. These individuals were
generally unable to continue beyond a cumulative dose of
13.88 units methacholine, and had significantly greater
breathing difficulty at 1.375 units methacholine that persisted
when tested with 13.88 units.
The number of subjects tested with 63.88 units methacholine
differed between baseline, low n-3 PUFA, and high n-3
PUFA ingestion (Table 2). Of the 19 subjects screened at
baseline, only five were given this dose of methacholine. After
high n-3 PUFA ingestion, 11 participants were tested with
63.88 units. Eight of nine responders were tested with 63.88
units after ingestion of the high fish-oil treatment compared
with four of nine at baseline. Conversely, only 3 of 10 nonresponders were tested with 63.88 units methacholine with high n-3 PUFA ingestion.
Nonresponders’ respiratory capacity appeared to be hindered
by high n-3 PUFA ingestion (Figures 1). Compared with
baseline, nonresponders’ FEV1, FVC, and PEF values were significantly lower with high n-3 PUFA ingestion at a
cumulative dose of 1 3.88 units methacholine. The only exception to this pattern occurred for FEF25-75 (Figure 1). Whereas the PD20 values for FEV1, FVC, and PEF were reduced by 85%, 71%, and 79%, respectively, with high n-3 PUFA ingestion, small
airway capacity-as assessed by FEF25-75 — actually improved by 10% (Table 1). Four nonresponders were eliminated at a cumulative dose of 1.375 units methacholine. At 63.88 units, the three remaining subjects were characterized by respiratory capacities not significantly different from those at baseline.
Leukotriene quantitation
In all participants, the lower ratio of n- 3 to n-6 PUFAs, ie,
0.1:1, was associated with an increase (13.2 ± 4.5 ng, P <
0.05) in total 4-series leukotriene excretion and a nonsignificant increase (7.8 ± 1.4 ng) in LTE5 excretion. At low n-3 PUFA ingestion, there was no significant difference in 4-series, S-series, or overall leukotriene excretion between responders and nonresponders (Figure 2).
With high n-3 PUFA ingestion, 4-series leukotriene excretion
was not different from baseline for responders or nonresponders
(Figure 2). However, in both groups, overall 4-series
leukotriene excretion was significantly lower (P < 0.05) with
high than with low n-3 PUFA ingestion. High n-3 PUFA
ingestion was associated with marked increases in LTE5 excretion
compared with baseline in both responders and nonresponders
(P < 0.05). High n - 3 PUFA consumption resulted in no changes in urinary 4-series leukotriene excretion in responders and nonresponders. The 5-series leukotriene excretion with high n-3
PUFA intake was 230% higher in responders (P < 0.05)
DISCUSSION
Ingestion of the n-3 PUFAs found in fish oil reduces total
leukotriene formation ≤40% and 4-series leukotriene production
by > 75% after an inflammatory stimulus in mice. [17] To
date, studies examining the effect of dietary n-3 PUFA consumption
on asthmatic symptoms have yielded equivocal results. [19–23] Cells present in human bronchi are capable of
metabolizing EPA to 5-series leukotrienes. [25] Dry and Vincent [21] showed an elevation in FEV1 values after feeding 1 g
docosahexaenoic acid (DHA, 22:6n-3) plus EPA daily for 1 y.
However, it is not clear whether they simply assessed FEV1
every 3 mo or if an asthmatic response was elicited through the
use of a specific agonist. Arm et al [19] showed that n-3
PUFA ingestion in asthmatic patients altered tissue phospholipid
composition and neutrophil LTB4 and LTB5 metabolism but did not cause any significant change in airway responsiveness to a histamine challenge. Additional studies are necessary to assess potential mechanisms by which n-3 PUFA ingestion may affect the course of asthma. A specific balance of n-3 with n-6 PUFAs, rather than absolute consumption of n-3 PUFAs, may be the critical factor that can alter synthesis of inflammatory metabolites. [28]
The eicosanoids may have a role in the rate of progression of
numerous disease processes, with the SPLTs implicated in
inflammatory conditions of the skin (psoriasis) [29], lung (allergic asthma) [30], and joints (rheumatoid arthritis). [31] Recent recommendations to increase fish consumption are motivated by research results that show that when n-3 PUFAs are present at a dietary ratio of between 1:5 and 1:2.5 with dietary n-6 PUFAs (found in vegetable oil) there is a reduction in overall eicosanoid production that may reduce the risk of a host of pathophysiologies. [17, 24, 32]
In the present study dietary supplementation with fish oil at
a ratio of n-3 to n-6 PUFAs of 0. 1: 1 for 1 mo tended to
diminish respiratory capacity in asthmatics. In contrast, when
the ratio of n-3 to n-6 PUFAs was increased to 0.5:1 , > 40%
of those tested showed significant respiratory benefit after
methacholine challenge. The average low and high dose of fish
oil provided ~0.7 and 3.3 g EPA and DHA daily, respectively.
Previously, it was reported that consumption of I g DHA +
EPA/d for 1 y beneficially altered FEV1 values in allergic
asthmatic patients. [21] A similar study that used 5.4 g EPA + DHA/d for 10 wk did not show any effect in the total subject
population after histamine challenge. [19] However, 6 of the 11
subjects showed minor respiratory improvements. In a subsequent
study [20], subjects who consumed n-3 PUFAs as
Max-EPA (Seven Seas, Marfleet Hall, United Kingdom) did
not show respiratory improvements immediately after histamine
challenge, but showed significant improvements in their
recovery periods. These findings, when considered in conjunction
with the present data, indicate that n-3 PUFAs, when
consumed long enough or in high enough amounts, may help to
ameliorate asthmatic symptoms in a portion of the asthmatic
population. Further studies will be necessary to determine why
some asthmatics benefit from n-3 PUFA ingestion whereas others do not.
Rather than the absolute amount of n-3 or n-6 PUFA
ingested, the ratio of n-3 to n-6 PUFAs is the critical factor
for altering eicosanoid biosynthesis in rats. [28] In previous
human studies the investigators did not indicate whether n-6
PUFA ingestion was controlled for. [19, 20] If the critical ratio of n-3 to n-6 PUFAs necessary to markedly alter leukotriene biosynthesis is not achieved, there may be no respiratory benefit from n-3 PUFA ingestion, even among responding individuals.
The beneficial change in respiratory indexes documented in
responders may be attributable primarily to an overall increase
in 5-series SPLT production. A necessary shift in leukotriene
biosynthesis (ie, an increase in S-series leukotriene coupled
with a reduction in 4-series leukotriene synthesis) to a point
where the ratio of 5- to 4-series leukotrienes is > 1 seems to be critical for mediating an improved response to methacholine
challenge. Furthermore, the ineffectiveness of n-3 PUFA ingestion in nonresponders was associated with a blunted increase in 5-series leukotriene production. Because urinary leukotriene excretion was not reported in the previous studies
cited [20, 21], the relation we report between diet-induced
elevations in 5-series SPLT production and improvements in
respiratory indexes may be a new finding of key physiologic
significance. The 5-series leukotrienes have been shown to be
less biologically potent in guinea pig ileum [33] and EPA has
been shown to inhibit the release of anaphylactic cyclooxygenase
products in guinea pig lung parenchymal strips while
enhancing SPLT release. [34] The respiratory benefit associated
with n-3 PUFA ingestion in responders could be associated
with the inability of 5-series leukotrienes to elicit an
asthmatic response, or by competitive inhibition by 5-series
leukotrienes at the 4-series leukotriene receptors.
In summary, the incorporation of a source of n-3 PUFA in
the diet, ie, fish or fish oil, could alleviate minor respiratory problems in asthmatics or decrease the degree of respiratory problems among a subset of severe asthmatics who respond to diet. Increased consumption of n-3 PUFAs can produce beneficial alterations in 4- and 5-series leukotriene synthesis.
These findings raise the possibility that dietary supplementation with marine oils or highly enriched sources of n-3 PUFAs may be another viable treatment modality for asthma.
References:
Fleming DM, Crombie DL. Prevalence of asthma and hay fever in
England and Wales. Br Med I 1987:294:279-83.
Kaliner M, Eggleston PA, Mathews KP. Rhinitis and asthma. IAMA
l987;258:285 1-71.
Dahl#{233}nSE, Hedquist P. Hammarstrom 5, Samuelson B. Leukotrienes
are potent constrictors of human bronchi. Nature 1980;288:484-6.
Chagnon M, Gentile I, Glada M, Sirios P. The mechanism of action of
leukotrienes A4, C4 and D4 on human lung parenchyma in vitro. Lung
1985; 163:55-62.
Henderson WR. Role of leukotrienes in asthma. Ann Allergy
1994:72:272-8.
Weller PF, Lee CW, Foster DW, Corey El, Austen KF, Lewis RA.
Generation and metabolism of 5-lipoxygenase pathway leukotrienes
by human eosiophils: predominant production of LTC 4. Proc Nail
Acad Sci U S A 1983:80:7626-30.
Peters SP, MacGlashan DW, Schulman ES, et al. Arachidonic acid
metabolism in purified human lung mast cells. I Immunol
1984;l32: 1972-9.
Chavis C, Godard P. Michel FB, Crastes de Paulet A, Damon M.
Sulfidopeptide leukotrienes contribute to human alveolar macrophage
activation in asthma. Prostaglandins Leukot Essent Fatty Acids
1991 ;42:95-100.
Maltby NH, Taylor GW, Ritter IM, Moore K, Fuller RW, Dollery CT.
Leukotriene C elimination and metabolism in man. I Allergy Clin
Immunol 1990:85:3-9.
Kikawa Y, Hosoi 5, Inoue Y, et al. Exercise-induced urinary excretion
of leukotnene E4 in children with atopic asthma. Pediatr Res
1991 ;29:455-9.
Westcott JY, Smith HR. Wenzel SE, et al. Urinary leukotriene E4 in
patients with asthma. Effect of airways reactivity and sodium cromoglycate.
Am Rev Respir Dis l991;143:1322-6.
Knapp HR. Sladek K, Fitzgerald GA. Increased excretion of leukotriene
E4 during aspirin-induced asthma. I Lab Clin Med
1992;1 19:48-51.
Lewis RA, Austen KF, Soberman Ri. Leukotrienes and other products
of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology
in human diseases. N Engl I Med 1990:323:645-55.
Nagai H, Yakuo I, Arimura A, Choi SH, Inagaki N, Koda A. Antiasthmatic
activity of newly synthesized calcium antagonists: 2-nbutyl-
1 (N-methyl-n-12-(N’,N’-dimethylamino)ethyllamino-5,6-methylenedioxy-
indene and indane. Int Arch Allergy AppI Immunol
1989;90: 137-43.
Kreutner W, Sherwood I, Rizzo C. The effect of leukotriene antagofists,
lipoxygenase inhibitors and selected standards on leukotrienemediated
allergic bronchospasm in guinea pigs. Agents Actions
l989;28: 173-84.
Dinh-Xuan AT, Regnard I, Similowski I, Rey I, Marsac I, Lockhart
A. Effects of SK&F 104353, a leukotriene receptor antagonist, on the
bronchial responses to histamine in subjects with asthma: a comparalive
study with terfenadine. I Allergy Clin Immunol 1990;85:865-71.
Broughton KS, Whelan I, Hardardottir I, Kinsella JE. The effect of
increasing the dietary n-3 to n-6 polyunsaturated fatty acid ratio on
murine liver and peritoneal cell fatty acids and eicosanoid metabolism.
I Nutr 1991:121:155-64.
Hargreave FE, Ryan G, Thomson NC, et al. Bronchial responsiveness
to histamine or methacholine in asthma: measurement and clinical significance. I Allergy Clin Immunol 1981:68:347-55.
Arm P1, Horton CE, Mencia-Huerta JM, et al. Effect of dietary
supplementation with fish oil lipids on mild asthma. Thorax
1988;43:84-92.
Arm IP, Horton CE, Spur BW, Mencia-Huerta JM, Lee TH. The
effects of dietary supplementation with fish oil lipids on the airways
response to inhaled allergen in bronchial asthma. Am Rev Respir Dis
1989; 139: 1395-400.
Dry I, Vincent D. Effect of a fish oil diet on asthma: results of a 1-year
double-blind study. Int Arch Allergy Appl Immunol l991;95:156-7.
Kirsch CM, Payan DG, Wong MYS. The effect of eicosapentaenoic
acid in asthma. Clin Allergy 1988:18:177-87.
Picado C, Castillo IA, Schinca N, et al. Effects of a fish oil diet on
aspirin intolerant asthmatic patients: a pilot study. Thorax l988;43:
93-7.
Whelan I, Broughton KS, Lokesh B, Kinsella IE. In vivo formation of
leukotriene E? by murine peritoneal cells. Prostaglandins
1991:41:29-42.
Broughton KS, Morgan U. Frequency of (n-3) polyunsaturated fatty
acid consumption induces alterations in tissue lipid composition and
eicosanoid synthesis. I Nutr 1994:124:1104-11.
Orning L, Bernstrm K, Hammarstrom S. Formation of leukotrienes E3,
E4 and E? in basophilic leukemia cells. Eur I Biochem 198 l;120:44-5.
Kirk BE. Experimental design. 2nd ed. Belmont, CA: Brooks/Cole
Publishers, 1982.
Boudreau MD, Chanmugam PS, Hart SB, Lee SH, Hwang DH. Lack
of dose response by dietary n - 3 fatty acids at a constant ratio of n -3
to n-6 fatty acids in suppressing eicosanoid biosynthesis from arachidonic
acid. Am I Clin Nutr 19154:111-7.
Brain 5, Camp R, Dowd P. Kobza-Black A, Greaves M. The release of
leukotriene-B4-like material in biologically active amounts from the
lesional skin of patients with psoriasis. I Invest Dermatol l984;83:
70-3.
Chanarmn N, Johnston SL. Leukotrienes as a target in asthma therapy.
Drugs l994;47: 12-24.
Kremer IM, Lawrence DA, Iubiz W, et al. Dietary fish oil and olive oil
supplementation in patients with rheumatoid arthritis. Arthritis Rheum
l990;33:810-20.
Hwang DH, Boudreau M, Chanmugam P. Dietary linolenic acid and
longer-chain n-3 fatty acids: comparison on arachidonic acid metabolism
in rats. I Nutr 1 18:427-37.
Hammarstrom S. Leukotriene C5: a slow reacting substance derived
from eicosapentaenoic acid. I Biol Chem 1980;255:7093-4.
Simmet I, Aissa I, Sutter D, Juan H, Peskar BA. Modulation of the
contractile activity of the guinea-pig lung parenchymal strip by exogenous
5,8,1l,14,l7-eicosapentaenoic acid. Arch Pharm (Weinheim)
1987;335:652-9.
Return to SHAKLEE STUDIES
Since 6-20-2017
|